SciClone Pharmaceuticals (Holdings) Limited
SciClone Pharmaceuticals (Holdings) Limited, headquartered in China, is a prominent player in the biopharmaceutical industry, specialising in the development and commercialisation of innovative therapies. Founded in 1995, the company has made significant strides in addressing unmet medical needs, particularly in oncology and infectious diseases. With a strong operational presence in Asia and expanding into global markets, SciClone is renowned for its flagship product, ZADAXIN, a thymosin alpha 1 therapy that enhances immune response. This unique offering positions the company as a leader in immunotherapy, catering to both patients and healthcare providers. SciClone's commitment to research and development, coupled with strategic partnerships, has solidified its market position, making it a key contributor to the advancement of biopharmaceutical solutions. The company continues to focus on delivering high-quality, effective treatments that improve patient outcomes worldwide.
DitchCarbon Score
How does SciClone Pharmaceuticals (Holdings) Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SciClone Pharmaceuticals (Holdings) Limited's score of 9 is lower than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
SciClone Pharmaceuticals (Holdings) Limited's reported carbon emissions
In 2023, SciClone Pharmaceuticals (Holdings) Limited reported total carbon emissions of approximately 97,500 kg CO2e, all of which fall under Scope 2 emissions. This represents a decrease from 90,100 kg CO2e in 2022 and a significant reduction from 292,800 kg CO2e in 2020. The company has demonstrated a commitment to reducing its carbon footprint, achieving a reduction of about 66% in its Scope 2 emissions over the three-year period from 2020 to 2023. Despite these reductions, there are currently no disclosed targets for further emissions reductions or specific climate pledges. The company has not provided data on Scope 1 or Scope 3 emissions, indicating a potential area for future focus in their sustainability efforts. As a pharmaceutical company headquartered in China, SciClone is positioned within an industry that is increasingly prioritising environmental responsibility and climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | - |
| Scope 2 | 292,800 | 000,000 | 00,000 | 00,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
SciClone Pharmaceuticals (Holdings) Limited is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
